PMID

Data

Article Title

Organization

Discovery of biaryls as ROR¿ inverse agonists by using structure-based design.

Biogen

Discovery of novel pyrazole-containing benzamides as potent ROR¿ inverse agonists.

Biogen

Identification of potent and novel alpha4beta1 antagonists using in silico screening.

Biogen

Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.

Biogen

Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.

Biogen

Discovery of Phospholipase D Inhibitors with Improved Drug-like Properties and Central Nervous System Penetrance.

Biogen

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.

Biogen

Discovery of Potent, Selective, and Brain-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors that Modulate Brain Inflammation

Biogen

Discovery of Potent Selective Nonzinc Binding Autotaxin Inhibitor BIO-32546.

Biogen

Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

Biogen

Novel Potent Selective Orally Active S1P5 Receptor Antagonists.

Biogen

Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.

Biogen

Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKC? phosphorylation: Potential therapy to modulate T cell dependent immunity.

Biogen

Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators.

Biogen

Discovery of CNS-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors.

Biogen

Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.

Biogen

Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses.

Biogen